Alpheus Medical Raises $52M to Advance Non-Invasive Glioblastoma Therapy into Phase 2B Trial

Chanhassen, MN, May 15, 2025 (PRNewswire) -- Alpheus Medical secured $52 million in Series B funding to advance a Phase 2B clinical trial of its non-invasive sonodynamic therapy for glioblastoma. The treatment uses low-intensity ultrasound and oral 5-ALA to selectively destroy tumor cells without imaging or sedation. Backed by top healthcare investors, the company aims to redefine the standard of care for one of the most lethal brain cancers.

Read full article here.